CTNI-44. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/mTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O(6)-METHYLGUANINE-METHYLTRANSFERASE PROMOTER

BACKGROUND: Paxalisib (GDC-0084) is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR). Paxalisib crosses the blood-brain barrier and achieves a brain / plasma ratio of approximately 1.0. An MTD of 60mg per day has be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wen, Patrick, de Groot, John, Battiste, James, Goldlust, Samuel, Damek, Denise, Garner, James, Simpson, Jeremy, Olivero, Alan, Cloughesy, Timothy
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650987/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.210
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados